Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02106975 · ClinicalTrials.gov registry record · Phase 2
Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT02106975 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 170 participants.
The verdict
NCT02106975, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ failure as measured by Sequential Organ Failure Assessment (SOFA) score, Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by the oxygenation index and the VE40 Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a fibrinolytic state (Tissue Factor Pathway Inhibitor).
Interventions
- DRUG Ascorbic Acid
- DRUG Placebo: 5% Dextrose in water
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-01-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02106975
The ClinicalTrials.gov registry entry for NCT02106975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ascorbic Acid is the first listed.
NCT02106975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02106975 about?
NCT02106975 is a clinical study titled "Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury". Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ failure as measured by Sequential Organ Failure Assessment (SOFA) score, Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by the oxygenation index and the VE40 Hypoth...
What is the current status of trial NCT02106975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2014-04. Estimated completion is 2018-01-08.
What interventions are being tested in trial NCT02106975?
The interventions under investigation include: Ascorbic Acid (DRUG), Placebo: 5% Dextrose in water (DRUG).
Who is sponsoring clinical trial NCT02106975?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.